Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Hyperlipoproteinemia Type II 1

Interventions

Magnetic Resonance Spectroscopy 11Oxaliplatin 9Fluorouracil 9Leucovorin 7Irinotecan 7Gemcitabine 7Nivolumab 6Biopsy 6Bevacizumab 6pembrolizumab 5lenvatinib 5Specimen Handling 5Radiosurgery 5Cisplatin 5Capecitabine 5X-Rays 4Radiation 4Proflavine 4Oncolytic Virotherapy 4Cyclophosphamide 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4sodium thiosulfate 3gallium 68 PSMA-11 3folfirinox 3Surgical Procedures, Operative 3Paclitaxel 3Omeprazole 3Ketamine 3Immune Checkpoint Inhibitors 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Ezetimibe × Gastrointestinal × Clear all
NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡